ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment
(NASDAQ:PRPH), U.S. Patent No. 12379378-B2 protects biomarker-driven systems and methods to assess progression risk in Barrett's esophagus and esophageal adenocarcinoma; issuance follows the successful BE-Smart(TM) test validation (>95% technical success) and, together with BE-Smart's demonstrated compatibility with both brush and forceps biopsies, supports earlier detection. UNIONDALE, NY, Aug. 12, 2025 (GLOBE NEWSWIRE) — ProPhase Labs, […]